Posted on 14 November 202414 November 2024 AstraZeneca and Merck’s Koselugo delivers phase 3 trial win in adults with NF1, teeing up filings Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1), Ast...